UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-40743 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended trans ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation) Delaware 86-1916231 (IRS Employer Identification Number) For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

[Corporate and Clinical Highlights](index=1&type=section&id=Corporate%20and%20Clinical%20Highlights) Tenax Therapeutics is advancing its lead program, TNX-103, for patients with PH-HFpEF, with Phase 3 LEVEL study enrollment ongoing and a second global Phase 3 study, LEVEL-2, set to begin in 2025, alongside operational team strengthening and patent protection extension to 2040 - Enrollment for the Phase 3 LEVEL study of TNX-103 (oral levosimendan) is ongoing, with the target expanded to **230 patients** to increase statistical power, expecting completion in the first half of 2026 and topline data in the second half of 2026[1](index=1&type=chunk)[2](index=2&type=chunk)[6](index=6&type=chunk) - A second registrational Phase 3 study, LEVEL-2, is on track to be initiated in 2025, with a global footprint including over **85 new sites** in **15 additional countries** already qualified[1](index=1&type=chunk)[2](index=2&type=chunk)[6](index=6&type=chunk) - The company expanded its operations team with new heads of Clinical Operations, Data Management, Pharmacovigilance, and Quality Assurance to oversee the LEVEL program[6](index=6&type=chunk) - In August 2025, the Canadian Intellectual Property Office allowed claims for a patent covering the use of levosimendan (TNX-103, TNX-102, TNX-101) in PH-HFpEF patients, extending patent protection to **2040** once granted[6](index=6&type=chunk) [Second Quarter 2025 Financial Results](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results) For the second quarter of 2025, Tenax Therapeutics reported a net loss of $10.9 million, driven by increased R&D and G&A expenses, while maintaining a strong cash position of $105.5 million expected to fund operations through 2027 - The company reported cash and cash equivalents of **$105.5 million** as of June 30, 2025, which is expected to fund operations through 2027[5](index=5&type=chunk) Financial Metric Comparison (in millions) | Financial Metric | Q2 2025 | Q2 2024 | Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | **R&D Expenses** | $6.1 | $2.3 | +$3.8 | Increased clinical development costs for LEVEL & LEVEL-2 studies, higher personnel costs | | **G&A Expenses** | $5.7 | $1.3 | +$4.4 | Primarily due to a $3.6 million increase in non-cash stock-based compensation | | **Net Loss** | $10.9 | $3.6 | +$7.3 | Driven by higher operating expenses | [Financial Statements](index=3&type=section&id=Financial%20Statements) The consolidated financial statements detail the company's financial performance and position, showing a significant year-over-year increase in operating expenses and net loss for both the three and six months ended June 30, 2025, alongside a strong cash position and increased total assets and stockholders' equity compared to year-end 2024 [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) For the three months ended June 30, 2025, total operating expenses were $11.8 million, leading to a net loss of $10.8 million, primarily driven by higher R&D and G&A spending compared to the same period in 2024 Three Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Research and development | $6,121 | $2,327 | | General and administrative | $5,671 | $1,344 | | **Total operating expenses** | **$11,792** | **$3,671** | | **Net loss** | **($10,847)** | **($3,575)** | | Net loss per share | ($0.27) | ($1.83) | Six Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Research and development | $11,804 | $5,003 | | General and administrative | $11,326 | $2,577 | | **Total operating expenses** | **$23,130** | **$7,580** | | **Net loss** | **($21,255)** | **($7,374)** | | Net loss per share | ($0.56) | ($4.65) | [Consolidated Balance Sheets](index=3&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, Tenax reported total assets of $105.9 million, primarily cash and cash equivalents, with total liabilities of $2.5 million and stockholders' equity of $103.3 million, indicating an increase in cash and equity from December 31, 2024 Balance Sheet Comparison (in thousands) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $105,462 | $94,851 | | **Total assets** | **$105,857** | **$96,686** | | Total liabilities | $2,527 | $4,693 | | **Total stockholders' equity** | **$103,330** | **$91,993** | [About Tenax Therapeutics and Levosimendan](index=2&type=section&id=About%20Tenax%20Therapeutics%20and%20Levosimendan) Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on novel cardiopulmonary therapies, with its lead candidate, levosimendan, being developed for PH-HFpEF, a condition currently lacking approved treatments - Tenax is a Phase 3 development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies[11](index=11&type=chunk) - The lead candidate, levosimendan, is a novel, first-in-class K-ATP channel activator/calcium sensitizer being evaluated in oral (TNX-103), IV (TNX-101), and subcutaneous (TNX-102) formulations[10](index=10&type=chunk) - The company is developing levosimendan for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date[11](index=11&type=chunk)

Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program The Company's lead product, PF614, is a Trypsin-Activated Abuse Protection (TAAP) extended-release oxycodone and a potential "next generation" analgesic to treat severe pain. PF614's TAAP che ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40544 Jade Biosciences, Inc. (Exact name of registrant as specified in its charter) Nevada 8 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ______ Commission File Number 001-41322 BLUEROCK HOMES TRUST, INC. (Exact name of registrant as specified in its charter) Marylan ...

Exhibit 99.1 BOSTON OMAHA CORPORATION ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Omaha, Nebraska (Business Wire) August 13, 2025 Boston Omaha Corporation (NYSE: BOC) (the "Company", "we", or "our") announced its financial results for the second quarter ended June 30, 2025, in connection with filing its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. As of August 12, 2025, we had 30,872,876 shares of Class A common stock and 580,558 shares of Class B common stock outstanding. ...

[Financial Highlights & CEO Commentary](index=1&type=section&id=Financial%20Highlights%20%26%20CEO%20Commentary) StandardAero achieved strong Q2 2025 results with double-digit revenue growth, improved net income and Adjusted EBITDA margins, and raised full-year targets Q2 2025 Financial Performance | Metric | Q2 2025 | YoY Change | | :--- | :--- | :--- | | Revenue | $1,528.9 million | +13.5% | | Net Income | $67.7 million | +$62.3 million | | Net Income Margin | 4.4% | +400 bps | | Adjusted EBITDA | $204.6 million | +20.1% | | Adjusted EBITDA Margin | 13.4% | +80 bps | - The CEO attributed the strong results to solid execution, a robust commercial aerospace aftermarket, and significant milestones in the LEAP engine program, which now has bookings exceeding **$1.5 billion**[3](index=3&type=chunk)[8](index=8&type=chunk) [Second Quarter 2025 Performance Analysis](index=1&type=section&id=Second%20Quarter%202025%20Performance%20Analysis) Q2 2025 performance saw broad growth across segments and markets, with net income surging due to higher operating income and reduced interest expenses, improving the leverage ratio [Consolidated Financial Results](index=1&type=section&id=Consolidated%20Financial%20Results) Consolidated revenue grew **13.5% to $1.53 billion**, with net income surging to **$67.7 million** due to improved operating income and lower interest expense, while Adjusted EBITDA margin expanded and leverage improved - Revenue growth was strong across all end markets: **commercial aerospace (+13.7%)**, **business aviation (+8.9%)**, and **military/helicopter (+11.7%)**, with the latter boosted by the ATI acquisition[4](index=4&type=chunk) Consolidated Financial Metrics | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue | $1,528.9 M | $1,347.2 M | | Net Income | $67.7 M | $5.4 M | | Adjusted EBITDA | $204.6 M | $170.4 M | | Net Debt | $2,262.5 M | $3,266.0 M | | Net Debt to Adj. EBITDA | 3.0x | 5.4x | [Segment Performance](index=1&type=section&id=Segment%20Performance) Both Engine Services and Component Repair Services segments achieved strong revenue growth and margin expansion, with Component Repair notably boosted by the ATI acquisition and **31.3%** revenue growth Engine Services Segment Performance | Engine Services Segment | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue | $1,350.7 M | $1,211.5 M | | Adjusted EBITDA | $178.5 M | $153.7 M | | Adjusted EBITDA Margin | 13.2% | 12.7% | Component Repair Services Segment Performance | Component Repair Services Segment | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue | $178.3 M | $135.7 M | | Adjusted EBITDA | $51.6 M | $34.5 M | | Adjusted EBITDA Margin | 29.0% | 25.4% | - The Component Repair Services segment's revenue growth included a **$27.3 million** contribution from the ATI acquisition[10](index=10&type=chunk) [Full Year 2025 Guidance](index=2&type=section&id=Full%20Year%202025%20Guidance) StandardAero raised its full-year 2025 guidance, projecting higher revenue and Adjusted EBITDA with improved segment margins, driven by strong first-half performance and sustained market demand FY 2025 Financial Guidance | FY 2025 Guidance | Updated | Prior | | :--- | :--- | :--- | | Revenue | $5,875 - $6,025 M | $5,825 - $5,975 M | | Adjusted EBITDA | $790 - $810 M | $775 - $795 M | | Engine Services Margin | 13.3% | ~13% | | Comp. Repair Services Margin | 28.3% | ~27% | | Free Cash Flow | $155 - $175 M | Unchanged | End Market Revenue Growth Assumptions | End Market Revenue Growth Assumptions | | | :--- | :--- | | Commercial Aerospace | Mid-Teens Growth | | Military & Helicopter | High Single Digit Growth | | Business Aviation | High Single Digit Growth | - The company expects compounding benefits in the coming years from its growth initiatives, including key platform programs and capacity expansion, which are anticipated to drive revenue growth, margin expansion, and attractive free cash flow[12](index=12&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) This section presents StandardAero's unaudited condensed consolidated financial statements, including Balance Sheets, Statements of Operations, and Statements of Cash Flows [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets increased to **$6.48 billion** as of June 30, 2025, with total stockholders' equity growing to **$2.51 billion** due to increased paid-in capital and reduced accumulated deficit Condensed Consolidated Balance Sheets (in thousands) | Balance Sheet (in thousands) | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Current Assets | $2,769,014 | $2,485,134 | | Total Assets | $6,482,711 | $6,213,601 | | Total Current Liabilities | $1,285,227 | $1,273,544 | | Long-Term Debt | $2,295,131 | $2,207,977 | | Total Liabilities | $3,969,428 | $3,840,197 | | Total Stockholders' Equity | $2,513,283 | $2,373,404 | [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 net income significantly increased to **$67.7 million**, driven by **13.5%** revenue growth and reduced interest expense, resulting in diluted EPS of **$0.20** Condensed Consolidated Statements of Operations (in thousands) | Income Statement (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenue | $1,528,943 | $1,347,198 | | Operating Income | $135,570 | $105,077 | | Interest Expense | $43,835 | $78,051 | | Net Income | $67,713 | $5,404 | | Diluted EPS | $0.20 | $0.02 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash used in operating activities was **$21.1 million**, with **$72.4 million** used in investing and **$81.7 million** provided by financing, ending with **$91.5 million** in cash Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(21,103) | $(18,154) | | Net cash used in investing activities | $(72,371) | $(44,776) | | Net cash provided by financing activities | $81,714 | $65,912 | | Net (decrease) increase in cash | $(11,068) | $2,292 | | Cash at end of the period | $91,513 | $60,274 | [Supplemental Financial Information & Reconciliations](index=10&type=section&id=Supplemental%20Financial%20Information%20%26%20Reconciliations) This section details financial breakdowns by segment and reconciles GAAP measures to non-GAAP metrics such as Adjusted EBITDA, Net Debt, and Free Cash Flow [Segment Financial Details](index=10&type=section&id=Segment%20Financial%20Details) In Q2 2025, Engine Services generated **$1.35 billion** revenue and **$178.5 million** Adjusted EBITDA, while Component Repair Services achieved **$178.3 million** revenue and **$51.6 million** Adjusted EBITDA, with both segments showing growth Q2 2025 Segment Results (in thousands) | Q2 2025 Segment Results (in thousands) | Revenue | Segment Adjusted EBITDA | Margin | | :--- | :--- | :--- | :--- | | Engine Services | $1,350,677 | $178,509 | 13.2% | | Component Repair Services | $178,266 | $51,640 | 29.0% | [Reconciliation of Non-GAAP Measures](index=12&type=section&id=Reconciliation%20of%20Non-GAAP%20Measures) The company provides reconciliations for key non-GAAP metrics, including Adjusted EBITDA, Net Debt, and Free Cash Flow, for Q2 2025 and as of June 30, 2025 Reconciliation: Net Income to Adjusted EBITDA (Q2 2025, in thousands) | Reconciliation: Net Income to Adjusted EBITDA (Q2 2025, in thousands) | | | :--- | :--- | | Net income | $67,713 | | Income tax expense | $24,022 | | Depreciation and amortization | $48,547 | | Interest expense | $43,835 | | Other adjustments | $20,520 | | **Adjusted EBITDA** | **$204,637** | Reconciliation: Debt to Net Debt (June 30, 2025, in millions) | Reconciliation: Debt to Net Debt (June 30, 2025, in millions) | | | :--- | :--- | | Total Debt | $2,354.0 | | Less: Cash | $91.5 | | **Net Debt** | **$2,262.5** | Reconciliation: Cash Flow to Free Cash Flow (Q2 2025, in millions) | Reconciliation: Cash Flow to Free Cash Flow (Q2 2025, in millions) | | | :--- | :--- | | Cash Flow from Operations | $2.9 | | Total Capital Expenditures | $(33.7) | | **Free Cash Flow** | **$(30.8)** | [Important Disclosures](index=4&type=section&id=Important%20Disclosures) This section provides important disclosures, including safe harbor statements for forward-looking information and explanations of non-GAAP financial measures like Adjusted EBITDA [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) Forward-looking statements regarding future performance and financial targets are subject to significant risks and uncertainties, and actual results may differ materially - Forward-looking statements are intended to be covered by safe harbor provisions and involve known and unknown risks. The company does not undertake any obligation to update these statements[17](index=17&type=chunk)[21](index=21&type=chunk) [Non-GAAP Financial Measures](index=5&type=section&id=Non-GAAP%20Financial%20Measures) StandardAero uses non-GAAP financial measures like Adjusted EBITDA, Net Debt to Adjusted EBITDA, and Free Cash Flow to provide greater transparency into core operating results and evaluate performance - The company uses non-GAAP measures to exclude items that may not be indicative of core operating results, allowing for better comparison over time and with peers. A reconciliation of these measures to their most comparable GAAP counterparts is provided[22](index=22&type=chunk)[23](index=23&type=chunk)[26](index=26&type=chunk)

Exhibit 99.1 Verde Clean Fuels, Inc. Reports Q2 2025 Results HOUSTON – August 13, 2025 - Verde Clean Fuels, Inc. ("Verde" or "the Company") (NASDAQ: VGAS) today reported results for the second quarter and first half of 2025. "We continue to advance our plans to deploy our proprietary liquid fuels processing technology through the development of commercial production plants. To this end, we also continue to advance front-end engineering and design ("FEED") for the Permian Basin project, a proposed natural ga ...

Exhibit 99.1 Forward-Looking Statements Verde Clean Fuels, Inc. Reports Q2 2025 Results HOUSTON – August 13, 2025 - Verde Clean Fuels, Inc. ("Verde" or "the Company") (NASDAQ: VGAS) today reported results for the second quarter and first half of 2025. "We continue to advance our plans to deploy our proprietary liquid fuels processing technology through the development of commercial production plants. To this end, we also continue to advance front-end engineering and design ("FEED") for the Permian Basin pro ...